Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

Diabetic retinopathy, a leading cause of blindness in working-age adults, silently damages eyes through high blood sugar.

What is laser photocoagulation? A laser procedure that seals leaking blood vessels to slow vision loss in wet age-related ...

Ireland has a serious problem with high blood pressure. Our rates are among the highest in the world, and we have a poor ...

New Zealanders living with multiple sclerosis, breast cancer, eye conditions, and lung cancer will benefit from five medicines that Pharmac will fund from 1 December 2025.

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

DelveInsight's KLKB1 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

4D Molecular Therapeutics (4DMT) has announced an exclusive licence agreement with Otsuka Pharmaceutical to develop and market 4D-150, a treatment for wet age-related macular degeneration (wet AMD) ...

Samsung Bioepis Co., Ltd. announced today that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis’ two ophthalmology assets: BYOOVIZ ® (ranibizumab), ...